Tenascin C in radiation-induced lung damage: Pathological expression and serum level elevation

Area of Science:

• Oncology
• Radiotherapy
• Biomarker Discovery

Background:

• Radiation-induced lung damage (RILD) poses a significant challenge in lung cancer radiotherapy, with unpredictable severity.
• No established biomarkers currently exist for predicting RILD.
• Tenascin C (TNC), an extracellular matrix glycoprotein, is known for its role in tissue remodeling, inflammation, and fibrosis.

Observation:

• A case study of a 36-year-old man with stage IIIB lung adenocarcinoma treated with neoadjuvant radiotherapy.
• Histopathological analysis of the surgical specimen revealed TNC expression in areas of radiation pneumonitis.
• Serum TNC levels were observed to be elevated post-radiotherapy.

Findings:

• Tenascin C (TNC) expression was localized to the radiation pneumonitis region in lung tissue.
• Post-radiotherapy serum TNC levels were significantly higher than baseline.
• These findings suggest a potential role for TNC in the pathogenesis of RILD.

Implications:

• Tenascin C (TNC) is proposed as a potential biomarker for the onset and severity of radiation-induced lung damage.
• Further research is warranted to validate TNC as a reliable biomarker for RILD in lung cancer patients.
• This could lead to improved patient monitoring and personalized radiotherapy strategies.